447 related articles for article (PubMed ID: 15753368)
1. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
3. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
4. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
5. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
7. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
8. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
10. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
11. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
13. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
15. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
16. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
17. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
18. Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.
Plaza-Menacho I; van der Sluis T; Hollema H; Gimm O; Buys CH; Magee AI; Isacke CM; Hofstra RM; Eggen BJ
J Biol Chem; 2007 Mar; 282(9):6415-24. PubMed ID: 17209045
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
20. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]